The potential cost-effectiveness of HPV vaccination among girls in Mongolia

Luvsan, Munkh-Erdene; Vodicka, Elisabeth; Jugder, Uranbolor; Tudev, Undarmaa; Clark, Andrew R.; Groman, Devin; Otgonbayar, Dashpagam; Demberelsuren, Sodbayar; LaMongtagne, D. Scott; Pecenka, Clint

doi:10.1016/j.jvacx.2022.100161

Cited by 1 publication

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study evaluated the cost-effectiveness of HPV vaccination among girls and young women in Mongolia, using a discount rate of 3% and aggregated into an Incremental Cost-Effectiveness Ratio (ICER). The results showed that HPV vaccination in girls in Mongolia has a high probability of being a low-cost investment compared to no vaccination, with projected ICERs representing less than 20% of gross domestic product (GDP) per capita (USD 3735 in 2018) [8]. Another study assessed the cost-effectiveness of HPV vaccination for adolescent girls and boys in the UK to prevent six HPV-caused cancers (cervical, anal, vaginal, vulvar, penile, and oropharyngeal).…”

Section: Introductionmentioning

confidence: 99%

Using a Dynamic Model to Estimate the Cost-Effectiveness of HPV Vaccination in Iran

Hagens,

Sloof,

Janghorban

2024

Vaccines

View full text Add to dashboard Cite

This study aimed to determine the cost-effectiveness of vaccination against HPV. An age–sex structured dynamic disease transmission model was created to estimate the spread of HPV and the HPV-related incidence of cervical cancer (CC) in Iran. Sixteen age groups of men and women were incorporated to reflect the differences in sexual preferences, vaccination uptake, and disease-related outcomes. Three scenarios were evaluated by using an Incremental Cost-Effectiveness Ratio (ICER) with gained quality-adjusted life years (QALYs). ICER values below one gross domestic product (GDP) per capita are evaluated as highly cost-effective. Vaccination reduces the number of infections and CC-related mortality. Over time, the vaccinated group ages and older age groups experience protection. An initial investment is required and savings in treatment spending reduce the impact over time. Vaccinating girls only was found to be cost-effective, with an ICER close to once the GDP per capita. Vaccinating both sexes was shown to be less cost-effective compared to girls only, and vaccinating boys only was not found to be cost-effective, with an ICER between once and three times, and greater than three times the GDP per capita, respectively. The estimates are conservative since societal cost-saving and the impact of other HPV-related illnesses were not considered and would likely reduce the ICERs.

show abstract

Section: Introductionmentioning

confidence: 99%